Robotic Biologist Unravels Complex Problems
By LabMedica International staff writers Posted on 27 Oct 2011 |
Computers are now capable of automating the scientific process itself. An interdisciplinary group of scientists has taken a major step toward this objective by demonstrating that a computer can analyze unprocessed research data from a biologic system and derive the basic mathematical equations that describe the way the system operates.
According to the researchers, from Vanderbilt University (Nashville, TN, USA), Cornell University (Ithaca, NY, USA), and CFD Research Corp., Inc. (Huntsville, AL, USA), it is one of the most complicated scientific modeling hurdles that a computer has solved totally from scratch.
The article that described this accomplishment was published in the October 2011 issue of the journal Physical Biology and it is available online. The work was a collaboration between John P. Wikswo, a professor at Vanderbilt, Dr. Michael Schmidt, and Dr. Hod Lipson at the Creative Machines Lab at Cornell University, and Dr. Jerry Jenkins and Dr. Ravishankar Vallabhajosyula at CFDRC.
The system’s “brains,” which Prof. Wikswo has termed the Automated Biology Explorer (ABE), is in a novel piece of software called Eureqa, developed at Cornell and released in 2009. Drs. Schmidt and Lipson originally created Eureqa to design robots without going through the typical trial and error stage that is both slow and expensive. After it succeeded, they recognized that it could also be applied to solving science problems.
One of Eureqa’s initial achievements was identifying the fundamental laws of motion by studying the motion of a double pendulum, which Eureqa accomplished in a few hours when running on a personal computer (PC).
In 2006, Prof. Wikswo heard Dr. Lipson lecture about his research. “I had a ‘eureka moment’ of my own when I realized the system Hod had developed could be used to solve biological problems and even control them,” Prof. Wikswo said. Thus, he started talking to Dr. Lipson immediately after the lecture and they began a collaboration to adapt Eureqa to analyze biologic problems.
“Biology is the area where the gap between theory and data is growing the most rapidly,” said Dr. Lipson. “So it is the area in greatest need of automation.”
The biologic system that the researchers employed to assess ABE is glycolysis, the basic process that generates energy in a living cell. They focused particularly on the way in which yeast cells control fluctuations in the chemical compounds produced by the process. The researchers chose this specific system, called glycolytic oscillations, to perform a virtual test of the software because it is one of the most extensively studied biologic control systems. Dr. Jenkins and Dr. Vallabhajosyula used one of the processes’ detailed mathematical models to generate a data set corresponding to the measurements a scientist would make under various conditions. To increase the accuracy of the test, the researchers packed the data with a 10% random error. When they fed the data into Eureqa, it derived a set of equations that were almost identical to the known equations. “What’s really amazing is that it produced these equations a priori,” said Dr. Vallabhajosyula. “The only thing the software knew in advance was addition, subtraction, multiplication, and division.”
The capability to generate mathematical equations from scratch is what differentiates ABE from Adam, the robot scientist developed by Dr. Ross King and his colleagues at the University of Wales at Aberystwyth (UK).
Dr. Adam runs yeast genetics experiments and made international headlines two years ago by making a unique scientific discovery without direct human input. King fed Adam with a model of yeast metabolism and a database of genes and proteins involved in metabolism in other species. He also linked the computer to a remote-controlled genetics laboratory. This allowed the computer to generate hypotheses, then devise and conduct actual experiments to test them.
In order to give ABE the ability to run research such as Adam, Prof. Wikswo’s group is currently designing “laboratory-on-a-chip” technology that can be controlled by Eureqa. This will allow ABE to design and perform a wide range of basic biology experiments. Their first endeavor is focused on developing a microfluidics device that can assess cell metabolism.
“Generally, the way that scientists design experiments is to vary one factor at a time while keeping the other factors constant, but, in many cases, the most effective way to test a biological system may be to tweak a large number of different factors at the same time and see what happens. ABE will let us do that,” Prof. Wikswo said.
Related Links:
Vanderbilt University
Cornell University
CFD Research
According to the researchers, from Vanderbilt University (Nashville, TN, USA), Cornell University (Ithaca, NY, USA), and CFD Research Corp., Inc. (Huntsville, AL, USA), it is one of the most complicated scientific modeling hurdles that a computer has solved totally from scratch.
The article that described this accomplishment was published in the October 2011 issue of the journal Physical Biology and it is available online. The work was a collaboration between John P. Wikswo, a professor at Vanderbilt, Dr. Michael Schmidt, and Dr. Hod Lipson at the Creative Machines Lab at Cornell University, and Dr. Jerry Jenkins and Dr. Ravishankar Vallabhajosyula at CFDRC.
The system’s “brains,” which Prof. Wikswo has termed the Automated Biology Explorer (ABE), is in a novel piece of software called Eureqa, developed at Cornell and released in 2009. Drs. Schmidt and Lipson originally created Eureqa to design robots without going through the typical trial and error stage that is both slow and expensive. After it succeeded, they recognized that it could also be applied to solving science problems.
One of Eureqa’s initial achievements was identifying the fundamental laws of motion by studying the motion of a double pendulum, which Eureqa accomplished in a few hours when running on a personal computer (PC).
In 2006, Prof. Wikswo heard Dr. Lipson lecture about his research. “I had a ‘eureka moment’ of my own when I realized the system Hod had developed could be used to solve biological problems and even control them,” Prof. Wikswo said. Thus, he started talking to Dr. Lipson immediately after the lecture and they began a collaboration to adapt Eureqa to analyze biologic problems.
“Biology is the area where the gap between theory and data is growing the most rapidly,” said Dr. Lipson. “So it is the area in greatest need of automation.”
The biologic system that the researchers employed to assess ABE is glycolysis, the basic process that generates energy in a living cell. They focused particularly on the way in which yeast cells control fluctuations in the chemical compounds produced by the process. The researchers chose this specific system, called glycolytic oscillations, to perform a virtual test of the software because it is one of the most extensively studied biologic control systems. Dr. Jenkins and Dr. Vallabhajosyula used one of the processes’ detailed mathematical models to generate a data set corresponding to the measurements a scientist would make under various conditions. To increase the accuracy of the test, the researchers packed the data with a 10% random error. When they fed the data into Eureqa, it derived a set of equations that were almost identical to the known equations. “What’s really amazing is that it produced these equations a priori,” said Dr. Vallabhajosyula. “The only thing the software knew in advance was addition, subtraction, multiplication, and division.”
The capability to generate mathematical equations from scratch is what differentiates ABE from Adam, the robot scientist developed by Dr. Ross King and his colleagues at the University of Wales at Aberystwyth (UK).
Dr. Adam runs yeast genetics experiments and made international headlines two years ago by making a unique scientific discovery without direct human input. King fed Adam with a model of yeast metabolism and a database of genes and proteins involved in metabolism in other species. He also linked the computer to a remote-controlled genetics laboratory. This allowed the computer to generate hypotheses, then devise and conduct actual experiments to test them.
In order to give ABE the ability to run research such as Adam, Prof. Wikswo’s group is currently designing “laboratory-on-a-chip” technology that can be controlled by Eureqa. This will allow ABE to design and perform a wide range of basic biology experiments. Their first endeavor is focused on developing a microfluidics device that can assess cell metabolism.
“Generally, the way that scientists design experiments is to vary one factor at a time while keeping the other factors constant, but, in many cases, the most effective way to test a biological system may be to tweak a large number of different factors at the same time and see what happens. ABE will let us do that,” Prof. Wikswo said.
Related Links:
Vanderbilt University
Cornell University
CFD Research
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune... Read more
First-of-its-Kind Blood Test Detects Trauma-Related Diseases
In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more